WP
CHRS icon

Woodline Partners’s Coherus Oncology CHRS Stock Holding History

Woodline Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-322,680
Closed -$558K – 616
2024
Q2 		$558K Sell
322,680
-212,759
-40% -$428K 0.01% 494
2024
Q1 		$1.28M Buy
535,439
+35,439
+7% +$87.2K 0.01% 448
2023
Q4 		$1.67M Hold
500,000
– – 0.02% 387
2023
Q3 		$1.87M Hold
500,000
– – 0.02% 404
2023
Q2 		$2.13M Buy
+500,000
New +$2.95M 0.03% 419

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's CHRS Position: Q3 2024 in Review

Woodline Partners sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 322,680 shares — an estimated $558K sold.

Woodline Partners first reported a position in CHRS in Q2 2023 and held it in 5 quarters. The position peaked at $2.13M in Q2 2023. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Woodline Partners reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 322,680 Coherus Oncology shares in Q3 2024, an estimated $558K.
  • Woodline Partners first reported a position in Coherus Oncology in Q2 2023 and held it in 5 quarters.
  • Woodline Partners's Coherus Oncology position peaked at $2.13M in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.